scholarly journals The impact of promotional strategies of pharmaceutical companies on doctor’s recommendation of branded drugs: an empirical study on pharmaceutical industry in Sri Lanka

2018 ◽  
Vol 6 (0) ◽  
pp. 55
Author(s):  
M. M. T. Punchibandara
Keyword(s):  
Sri Lanka ◽  
Pharmaceutical Industry ◽  
Empirical Study ◽  
Pharmaceutical Companies ◽  
Branded Drugs ◽  
Promotional Strategies ◽  
The Impact

Impact of Pharmaceutical Industry Promotion Mix on Doctor's Prescribing Behaviour

2008 ◽  
Vol 4 (4) ◽  
pp. 82-95
Author(s):  
Girish Taneja
Keyword(s):  
Factor Analysis ◽  
Pharmaceutical Industry ◽  
Hypothesis Testing ◽  
Data Reduction ◽  
Sampling Method ◽  
Demographic Variables ◽  
Pharmaceutical Companies ◽  
Prescribing Behaviour ◽  
Promotional Strategies ◽  
The Impact

This study was conducted to develop a simple framework for finding out the impact of the different kinds of promotional tools offered by pharmaceutical industry on the prescribing behaviour of doctors. Moreover the study also focused on whether the perception of physicians towards various promotional tools is different with respect to demographic variables. Well-structured schedule was developed for conducting the study. Judgmental sampling method was followed. Survey was conducted and data was analyzed on the basis of responses provided by 523 respondents. Researcher has applied factor analysis for data reduction and ANOVA & F-test for hypothesis testing. Findings of the study can help the marketing managers of pharmaceutical companies in designing their promotional strategies especially for doctors.

scholarly journals TRANSFORMATIONAL TRENDS AND INNOVATIVE FACTORS IN THE DEVELOPMENT OF THE WHOLESALE AND RETAIL SECTORS OF THE PHARMACEUTICAL MARKET

2021 ◽  
pp. 27-35
Author(s):  
E. A. Bykova
Keyword(s):  
Pharmaceutical Industry ◽  
Structural Changes ◽  
State Regulation ◽  
Pharmaceutical Market ◽  
Essential Medicines ◽  
Pharmaceutical Companies ◽  
Innovative Development ◽  
Market Participants ◽  
The Impact

The article discusses important features of trends in the transformation of the wholesale and retail level of the Russian medicinal market in the context of innovative factors in the development of the pharmaceutical industry in Russia. The paper gives a general assessment of the impact of state regulation of the maximum selling prices for medicines from the list of vital and essential medicines on the profitability of the market. The author presents a simplified institutional scheme of interaction between distributors and other market participants. The study discusses important aspects and tactical steps of the distribution and pharmacy level of the Russian pharmaceutical market. The article gives the ratings of the leading distribution pharmaceutical companies in Russia and analyses the peculiarities of their structural changes under the influence of innovative development factors. The paper gives ratings of leading pharmacy chains and analyses the features of new structural formations – associations. The author proposes the term of “polarization” for wholesale and retail companies.

scholarly journals Open innovation: An opportunity for Pharmerging countries to close the technology gap?

2014 ◽  
Vol 5 (1) ◽  
pp. 19
Author(s):  
Hind Louiza Chitour
Keyword(s):  
Pharmaceutical Industry ◽  
Open Innovation ◽  
Health Expenditures ◽  
Pharmaceutical Companies ◽  
Closed Model ◽  
Health Market ◽  
Intangible Benefits ◽  
Critical Phase ◽  
Innovation Model ◽  
The Impact

The pharmaceutical industry is entering a critical phase in its history, with decliningprofits and patent cliffs fallouts awaiting their former blockbuster drugs. Several hypotheseshave been formulated to explain the causes of this downfall whether it is the drought in theirR&D pipelines, the rising competition of generics or the ever-increasingpressure from healthcareproviders such as governments seeking to curb their health expenditures thus causing priceerosion. However, rather than striving to find the root causes of the issues the industry isfacing, the major players in the Pharma field should focus on implementing measures totransform the very structure of the pharmaceutical companies and change the drug discoveryand commercialization processes. These core changes that the pharmaceutical sector has toundergo could be achieved through several methods. One of the most suggested solutions tothis R&D bottleneck could be shifting from the traditional “closed model” towards a new “openinnovation” model based on collaboration of Pharma companies whether it includes workingtogether with a biotech company, CROs, Academia or local Pharma manufacturer. This openinnovation model is believed to foster innovation and invigorate the agonizing R&D Pharmasector as it proved itself to be effective resulting in innovative projects and ideas in the ITsector. It is in this context that this paper will address the opportunity emerging pharmaceuticalmarkets could benefit from when this open innovation model is applied to the pharmaceuticalindustry. Mainly, we will discuss the integration of this strategy within big Pharma companiesin their efforts to enter what is designated as “Pharmerging countries” in general with a specialfocus on one key global health market: China. We will discuss the impact of this innovationstrategy could bring in terms of both tangible and intangible benefits and potential drawbacks.

The Impact of Information Systems on Management Performance in the Pharmaceutical Industry

2015 ◽  
Vol 17 (3) ◽  
pp. 56-73 ◽  
Author(s):  
Sherif Elshorbagy ◽  
Lalit Garg ◽  
Vipul Gupta ◽  
Gopalakrishnan Narayanamurthy ◽  
Yosuf Abd Al Oraini
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Companies ◽  
Successful Implementation ◽  
Strategic Decisions ◽  
Management Performance ◽  
Business Operations ◽  
Lack Of Information ◽  
Short Time ◽  
And Control ◽  
The Impact

There are many aspects that should be considered while implementing ISs in pharmaceutical companies. This is due to the various regulations and standards that the governmental authorities impose on these companies. In addition, any audit from US Food and Drug Administration (FDA) or other authorities will require computer system validation to be performed for the implemented ISs to ensure that all areas that affect the drugs lifecycle are following the required standards, and that each single process in this lifecycle is validated. Unfortunately, many pharmaceutical companies didn't recognize yet the importance of ISs to their businesses. The research presented in this paper examines the value of using an information system (IS) in pharmaceutical environment and how it can be a key component of improving the operational and process effectiveness by supporting the strategic decisions and enabling the decision-makers to take their decisions in short time. Lack of information in pharmaceutical companies is one of the reasons why these companies will not be able to compete in this competitive market because the delays in taking decisions, product lifecycle, and supply chain. Pharmaceutical companies required to follow various regulations and standards, and ISs are the tools that can be mapped to these standards and control the business operations without any obstacles. The authors conducted a comprehensive study to investigate the role of ISs in the pharmaceutical industry through a review of existing literatures relevant to the research subject and through a questionnaire survey with 54 participants working in the pharmaceutical industry in different countries in the Middle East. The survey aimed to understand the present status of ISs in pharmaceutical companies and the impact of ISs on management performance, operation improvement, end-users productivity, and compliance with the regulations and standards of the pharmaceutical industry in their companies. Moreover, the survey also aimed to identify the catalysts behind successful implementation of ISs.

scholarly journals CURRENT TRENDS IN INTERNATIONAL MERGERS AND ACQUISITIONS OF PHARMACEUTICAL COMPANIES

2021 ◽  
Vol 7 (2) ◽  
pp. 97-108
Author(s):  
Yana S. Sinitsova
Keyword(s):  
Pharmaceutical Industry ◽  
Mergers And Acquisitions ◽  
Statistical Data ◽  
Comprehensive Approach ◽  
Pharmaceutical Companies ◽  
High Significance ◽  
Geographical Structure ◽  
Current Trends ◽  
International Mergers ◽  
The Impact

The article analyzes the results of mergers and acquisitions of global pharmaceutical companies and  their  impact  on  the  global  pharmaceutical  industry.  The  relevance  of  this  research is determined by the high significance of mergers and acquisitions of global pharmaceutical companies on the global pharmaceutical industry and market. A comprehensive approach is used to assess the impact of mergers and acquisitions of pharmaceutical companies on the global pharmaceutical  industry.  The  article  presents  statistical  data  on  the  volume  and  number  of venture  investments  in  the  pharmaceutical  and  biotechnological  industries.  The  reasons  for mergers and acquisitions by pharmaceutical companies, as well as the dynamics of the activity of such transactions, are determined. The geographical structure of stock transactions and the total number of mergers and acquisitions of pharmaceutical companies are presented, as well as examples of the largest mergers and acquisitions of pharmaceutical companies.

scholarly journals Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study

BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e024928 ◽  
Author(s):  
Lisa Parker ◽  
Emily A Karanges ◽  
Lisa Bero
Keyword(s):  
Pharmaceutical Industry ◽  
Codes Of Conduct ◽  
Code Of Conduct ◽  
Regulatory System ◽  
Healthcare Sector ◽  
Pharmaceutical Companies ◽  
Reporting Requirements ◽  
Regulatory Systems ◽  
The Impact ◽  
Observational Database Study

ObjectivesTo describe and quantify disclosed payments from the pharmaceutical industry to the healthcare sector, and to examine the impact of the 2015 changes to Australia’s self-regulated system of transparency.DesignObservational database study.SettingAustralia.ParticipantsPublicly available reports submitted by members of Australian pharmaceutical industry trade organisations, Medicines Australia and the Generic and Biosimilar Medicines Association (GBMA) (October 2011–December 2017).ExposureChanges to transparency reporting requirements with the updates of pharmaceutical industry Codes of Conduct in 2015.Main outcome measuresElements of healthcare sector spending that members of industry organisations are required to publicly disclose; cumulative amount of disclosed spending (monthly average) in the year prior to and following the revision.ResultsThere was a 34.1% reduction in disclosed spending from Medicines Australia member companies in the year after the 2015 changes to the Code of Conduct were introduced ($A89 658 566 in the preceding year, October 2014–September 2015; $A59 052 551 in the following year). The new Code allowed for reduced reporting of spending on food and beverages at events and for sponsored healthcare professionals. However, there was enhanced transparency around identification of individual health professionals receiving payments. GBMA member reporting totalled $A2 580 402 in the year prior to the revision, then ceased.ConclusionsThis study shows the limitations of a self-regulatory system around industry disclosure of spending. We advocate for robust regulatory systems, such as legislation, to promote mandatory long-lasting public transparency.

Sign in / Sign up

Export Citation Format

Share Document